Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine

S. Rehberg; P. Enkhbaatar; D. L. Traber

doi:10.1007/978-0-387-92278-2_47

Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine

S. Rehberg, P. Enkhbaatar, D. L. Traber

Anesthesiology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

The calcium (Ca²⁺)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].

Original language	English (US)
Title of host publication	Yearbook of Intensive Care and Emergency Medicine 2009
Publisher	Springer New York
Pages	498-510
Number of pages	13
ISBN (Print)	9780387922775
DOIs	https://doi.org/10.1007/978-0-387-92278-2_47
State	Published - Dec 1 2007

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-0-387-92278-2_47

Fingerprint Dive into the research topics of 'Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine'. Together they form a unique fingerprint.

Cite this

@inbook{0b581f3dd4a5442ba356984c434c70ac,

title = "Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine",

abstract = "The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].",

author = "S. Rehberg and P. Enkhbaatar and Traber, {D. L.}",

year = "2007",

month = dec,

day = "1",

doi = "10.1007/978-0-387-92278-2_47",

language = "English (US)",

isbn = "9780387922775",

pages = "498--510",

booktitle = "Yearbook of Intensive Care and Emergency Medicine 2009",

publisher = "Springer New York",

}

TY - CHAP

T1 - Role of the calcium sensitizer, levosimendan, in perioperative intensive care medicine

AU - Rehberg, S.

AU - Enkhbaatar, P.

AU - Traber, D. L.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].

AB - The calcium (Ca2+)-sensitizer, levosimendan, is recommended by the European Heart Association and the European Society of Intensive Care Medicine for the treatment of low output heart failure, when standard treatment is insufficient [1]. Despite encouraging results from experimental and randomized clinical studies, a recent large randomized, double-blind, multicenter trial in patients with acute decompensated heart failure (Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support, SURVIVE study), did not reveal any significant reduction in 31- or 180-day mortality with levosimendan compared to dobutamine [2]. The elementary question that needs to be addressed and was recently elegantly worded by Dr. Butler and colleagues, is whether to abandon or not to abandon levosimendan? [3].

UR - http://www.scopus.com/inward/record.url?scp=77957246033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957246033&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-92278-2_47

DO - 10.1007/978-0-387-92278-2_47

M3 - Chapter

AN - SCOPUS:77957246033

SN - 9780387922775

SP - 498

EP - 510

BT - Yearbook of Intensive Care and Emergency Medicine 2009

PB - Springer New York

ER -